Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-28T03:44:53.873Z Has data issue: false hasContentIssue false

BNF limits v. threshold dosing

Published online by Cambridge University Press:  02 January 2018

Geoffrey F. Searle*
Affiliation:
Dorset Healthcare NHS Foundation Trust, UK, email: geoff.searle@dhft.nhs.uk
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Royal College of Psychiatrists, 2010

David Taylor is right that there is excessive polypharmacy in routine practice. Reference Taylor1 However, he does not examine or comment upon one of the root causes, British National Formulary (BNF) limits. Many clinicians seem to believe they are acting in the patient's interest by prescribing two compounds at close to the BNF maximum rather than one above this mark. As a clinician it is commonplace to come across patients who respond well to sub-BNF doses as well as those who are untouched by a drug at the BNF maximum dose. In the case of antipsychotic drugs, Agid et al Reference Agid, Mamo, Ginovart, Vitcu, Wilson and Zipursky2 have once again demonstrated that response to these drugs is related to the measured blockade of striatal receptors. As I suggested in my paper 12 years ago, Reference Searle3 this allows the clinician to quickly and accurately judge the sensitivity of an individual patient to antipsychotic treatment by increasing the dose rapidly to the point at which extrapyramidal side-effects are just discernible - and then waiting for a response. Following this threshold dosage scheme has led me to occasionally use a much wider range of doses than the BNF limits allow. For example, I have prescribed risperidone in schizophrenia with good effect at as little as 0.5 mg per day and as much as 32 mg per day, a 64-fold dose range. Although those who practise acute adult psychiatry often observe that patients with severe psychosis may be dramatically medication-resistant, unless they have used threshold dosing they do not know that the sensitivity of the patient to antipsychotic medication increases as their mental state improves, allowing a reduction in dose with maintained efficacy. It is worth remembering that BNF limits are usually established in accessible and responsive out-patient populations with moderate symptoms. Practising clinicians treat many patients who do not come from this population and may find themselves with a difficult choice: polypharmacy or prescription outside BNF limits.

References

1 Taylor, D. Antipsychotic polypharmacy – confusion reigns. Psychiatrist 2010; 34: 41–3.CrossRefGoogle Scholar
2 Agid, O, Mamo, D, Ginovart, N, Vitcu, I, Wilson, AA, Zipursky, RB, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response – a double-blind PET study in schizophrenia. Neuropsychopharmacology 2006; 32: 1209–15.Google ScholarPubMed
3 Searle, GF. Optimising neuroleptic treatment for psychotic illness. Psychiatr Bull 1998; 22: 548–51.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.